Fluctuations of CSF amyloid-β levels: Implications for a diagnostic and therapeutic biomarker

Neurology

Volumn 68, Issue 9, 2007, Pages 666-669

  Bateman, Randall J ^a   Wen, Guolin ^a   Morris, John C ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[1-X]; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CATHETER; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; ALZHEIMER DISEASE; CEREBROSPINAL FLUID; MIDDLE AGED; REFERENCE VALUE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TIME;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 33947507128     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000256043.50901.e3     Document Type: Article

References (14)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
2. Golde TE, Eckman CB, Younkin SG. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta 2000;1502:172-187.
3. 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer's disease. JAMA 2003;289:2094-2103.
4. Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998;44.
5. Andreasen N, Hess C, Davidsson P, et al. Cerebrospinal fluid β-amyloid(1-42) in Alzheimer's disease: differences between early- and late-onset Alzheimer's disease and stability during the course of disease. Arch Neurol 1999;56:673-680.
6. Hansson O, Zetterberg H, Buchlave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:293.
7. Han X, Fagan AM, Cheng H, Morris JC, Xiong C, Holtzman DM. Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann Neurol 2003;54:115-119.
8. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A beta(42) in humans. Ann Neurol 2006;59:512-519.
9. Cirrito JR, May PC, O'Dell MA, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 2003;23:8844-8853.
10. Vanderstichele H, De Meyer G, Andreasen N, et al. Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin Chem 2005;51:1650-1660.
11. Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 2000;48:913-918.
12. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006;12:856-861.
13. Cirrito JR, Yamada KA, Finn MB, et al. Synaptic activity regulates interstitial fluid amyloid-[beta] levels in vivo. Neuron 2005;48:913.
14. Kamenetz F, Tomita T, Hsieh H, et al. APP processing and synaptic function. Neuron 2003;37:925-937.